Axis-Shield Settles Homocysteine Patent Dispute
The Scotland-based company announced Wednesday that it has agreed to withdraw all patent infringement litigation against Diazyme and its partners. In exchange, Diazyme will withdraw opposition to Axis-Shield's homocysteine patents outside the U.S. and license them from Axis-Shield.
The companies’ enzymatic homocysteine assays test whether a person has a high level of the amino acid homocysteine, which could indicate the...
To view the full article, register now.